Literature DB >> 24519263

Influence of refill adherence method when comparing level of adherence for different dosing regimens.

A K Jönsson1, L Schiöler, E Lesén, K Andersson Sundell, A-C Mårdby.   

Abstract

PURPOSE: To examine the impact of two methods when estimating refill adherence in patients using bisphosphonates with different dosing regimens.
METHODS: In the Swedish Prescribed Drug Register, 18,203 new users of bisphosphonates aged 18-85 years were identified between 1 July 2006 and 30 June 2007 and followed for a maximum of 2 years. The patients were categorised based on dosing regimen: one tablet daily, one tablet weekly, switching between these regimens, and other regimens. Refill adherence was estimated with Continuous measure of Medication Acquisition (CMA, adherent if CMA ≥ 80 %) and the maximum gap method (adherent if gaps <45 days). Differences in adherence between patients in the groups were assessed with logistic regression models controlling for confounding factors.
RESULTS: The proportion of patients classified as adherent was higher using CMA compared with patients classified as adherent using the maximum gap method. Patients on one tablet weekly had significantly lower adherence compared with patients on one tablet daily in the main analyses of both methods (the maximum gap method: 73 % vs. 80 %; adjusted OR=0.71; 95 % CI 0.57-0.89 and CMA: 84 % vs. 88 %, adjusted OR=0.75; 95 % CI 0.57-0.99). Patients using the other two dosing regimens had significantly lower adherence compared with patients on one tablet daily using both methods.
CONCLUSION: Choice of method has an impact on the estimates of refill adherence to bisphosphonates. Patients on one tablet weekly dosing had lower adherence compared with patients on one tablet daily dosing using both methods.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24519263     DOI: 10.1007/s00228-014-1649-2

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  31 in total

1.  Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures.

Authors:  Lisa M Hess; Marsha A Raebel; Douglas A Conner; Daniel C Malone
Journal:  Ann Pharmacother       Date:  2006 Jul-Aug       Impact factor: 3.154

Review 2.  The Nordic countries as a cohort for pharmacoepidemiological research.

Authors:  Kari Furu; Björn Wettermark; Morten Andersen; Jaana E Martikainen; Anna Birna Almarsdottir; Henrik Toft Sørensen
Journal:  Basic Clin Pharmacol Toxicol       Date:  2009-12-04       Impact factor: 4.080

3.  Validity of a prescription claims database to estimate medication adherence in older persons.

Authors:  Ruby Grymonpre; Mary Cheang; Marjory Fraser; Colleen Metge; Daniel S Sitar
Journal:  Med Care       Date:  2006-05       Impact factor: 2.983

4.  Predictive factors for age at menopause in Caucasian females.

Authors:  Volodymyr Dvornyk; Ji-Rong Long; Peng-Yuan Liu; Lan-Juan Zhao; Hui Shen; Robert R Recker; Hong-Wen Deng
Journal:  Maturitas       Date:  2005-10-06       Impact factor: 4.342

5.  A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System.

Authors:  J Devine; S Trice; Z Finney; S Yarger; E Nwokeji; A Linton; W Davies
Journal:  Osteoporos Int       Date:  2011-07-23       Impact factor: 4.507

6.  An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients.

Authors:  Sudeep Karve; Mario A Cleves; Mark Helm; Teresa J Hudson; Donna S West; Bradley C Martin
Journal:  Med Care       Date:  2008-11       Impact factor: 2.983

Review 7.  Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis.

Authors:  I Imaz; P Zegarra; J González-Enríquez; B Rubio; R Alcazar; J M Amate
Journal:  Osteoporos Int       Date:  2009-12-05       Impact factor: 4.507

8.  Beliefs about medicines predict refill adherence to inhaled corticosteroids.

Authors:  Tanja T Menckeberg; Marcel L Bouvy; Madelon Bracke; Ad A Kaptein; Hubert G Leufkens; Jan A M Raaijmakers; Rob Horne
Journal:  J Psychosom Res       Date:  2008-01       Impact factor: 3.006

9.  Pharmacy benefits and the use of drugs by the chronically ill.

Authors:  Dana P Goldman; Geoffrey F Joyce; Jose J Escarce; Jennifer E Pace; Matthew D Solomon; Marianne Laouri; Pamela B Landsman; Steven M Teutsch
Journal:  JAMA       Date:  2004-05-19       Impact factor: 56.272

Review 10.  Update on osteoporosis management in long-term care: focus on bisphosphonates.

Authors:  Hosam K Kamel
Journal:  J Am Med Dir Assoc       Date:  2007-09       Impact factor: 4.669

View more
  5 in total

1.  Understanding Adherence and Prescription Patterns Using Large-Scale Claims Data.

Authors:  Margrét V Bjarnadóttir; Sana Malik; Eberechukwu Onukwugha; Tanisha Gooden; Catherine Plaisant
Journal:  Pharmacoeconomics       Date:  2016-02       Impact factor: 4.981

2.  Adherence to antidepressants among women and men described with trajectory models: a Swedish longitudinal study.

Authors:  Ann-Charlotte Mårdby; Linus Schiöler; Karolina Andersson Sundell; Pernilla Bjerkeli; Eva Lesén; Anna K Jönsson
Journal:  Eur J Clin Pharmacol       Date:  2016-08-03       Impact factor: 2.953

Review 3.  A VOSviewer-Based Bibliometric Analysis of Prescription Refills.

Authors:  Runchen Fu; Haiping Xu; Yongjie Lai; Xinying Sun; Zhu Zhu; Hengchang Zang; Yibo Wu
Journal:  Front Med (Lausanne)       Date:  2022-06-21

4.  Risk Factors for Fatal Hyperglycaemia Confirmed by Forensic Postmortem Examination - A Nationwide Cohort in Sweden.

Authors:  Lotta Walz; Anna K Jönsson; Brita Zilg; Carl Johan Östgren; Henrik Druid
Journal:  PLoS One       Date:  2016-10-21       Impact factor: 3.240

5.  Refill Adherence in Relation to Substitution and the Use of Multiple Medications: A Nationwide Population Based Study on New ACE-Inhibitor Users.

Authors:  Pernilla J Bjerkeli; Anna K Jönsson; Eva Lesén; Ann-Charlotte Mårdby; Karolina Andersson Sundell
Journal:  PLoS One       Date:  2016-05-18       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.